Showing results (271-280 of 653) with videos related to

Sort By:
Pageof 66
Breast Cancer Research : BCR|August 17, 2017
Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancerNatalia Paez Arango, Erkan Yuca, Ming Zhao, et al.
Cancer|January 24, 2025
A phase 2 basket study of talabostat, a small-molecule inhibitor of dipeptidyl peptidases, administered in combination with pembrolizumab in patients with advanced solid cancersJibran Ahmed, Filip Janku, Daniel D Karp, et al.
JAMA Network Open|May 6, 2024
KRAS Allelic Variants in Biliary Tract CancersGordon Taylor Moffat, Zishuo Ian Hu, Funda Meric-Bernstam, et al.
NPJ Breast Cancer|August 11, 2023
Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecanMing Zhao, Timothy P DiPeri, Maria Gabriela Raso, et al.
Molecular Cancer Therapeutics|April 15, 2011
PI3K pathway mutations and PTEN levels in primary and metastatic breast cancerAna M Gonzalez-Angulo, Jaime Ferrer-Lozano, Katherine Stemke-Hale, et al.
Breast Cancer Research and Treatment|February 26, 2009
Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast densityWei Tse Yang, Michael T Lewis, Kenneth Hess, et al.
Cancer|March 13, 2009
Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutationJennifer K Litton, Shannon N Westin, Kaylene Ready, et al.
International Journal of Radiation Oncology, Biology, Physics|September 30, 2016
Outcomes of Post Mastectomy Radiation Therapy in Patients Receiving Axillary Lymph Node Dissection After Positive Sentinel Lymph Node BiopsyMichael C Stauder, Abigail S Caudle, Pamela K Allen, et al.
Annals of Surgical Oncology|August 1, 2012
American College of Surgeons Oncology Group (ACOSOG) Z0011: impact on surgeon practice patternsAbigail S Caudle, Kelly K Hunt, Susan L Tucker, et al.
Experimental Hematology & Oncology|April 28, 2020
Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trialVivek Subbiah, Ecaterina Ileana Dumbrava, Yunfang Jiang, et al.
Pageof 66